China’s First PEG-Crosslinked Sodium Hyaluronate Gel Launched, a Made-in-TEDA Product

Recently, Tianjin JenKem Technology Co., Ltd., an enterprise in TEDA, launched its independently developed PEG-crosslinked sodium hyaluronate gel product. It is the first and only Class III medical device registered product of its kind in China. This marks a breakthrough in independent innovation in the field of high-end medical aesthetic fillers in the country.

In this product, PEG is innovatively selected as the crosslinking agent, which offers excellent biosafety and effectively avoids potential risks such as residual crosslinker-induced toxicity and sensitization. Clinical promotion in key medical institutions across the country has been initiated, and it is expected to fully enter the market by the fourth quarter of 2025.

Tianjin JenKem Technology Co., Ltd. was established in TEDA in 2007 as a wholly-owned subsidiary of Beijing JenKem Technology Co., Ltd. The company has developed and industrialized a production base for medical and pharmaceutical PEG derivatives in the West Zone of TEDA, possessing proprietary PEG synthesis and PEGylation technologies.